rss
Br J Ophthalmol 2006;90:856-860 doi:10.1136/bjo.2006.091579
  • Clinical science
    • Extended reports

Short term oral minocycline treatment of meibomianitis

  1. J D Aronowicz,
  2. W E Shine,
  3. D Oral,
  4. J M Vargas,
  5. J P McCulley
  1. Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
  1. Correspondence to: J P McCulley MD The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9057, USA; james.mcculley{at}Utsouthwestern.edu
  • Accepted 6 April 2006
  • Published Online First 13 April 2006

Abstract

Aim: To evaluate the clinical impact, aqueous tear parameters, and meibomian gland morphology in patients with primary meibomianitis before, during, and 3 months after a course of oral minocycline.

Methods: 16 patients were prospectively enrolled, 11 male and five female (mean age 69 years old). Each patient received routine clinical evaluations before, after 3 months therapy, and at 6 month study follow up visit. The clinical appearance, tear volume, flow and turnover, evaporation, Schirmer I test, meibomian gland dropout, lissamine green staining, and bacteriology wer evaluated.

Results: Improvement was observed in clinical signs of meibomianitis at the second and third visits. Microbial culture findings improved. Decreased aqueous tear volume and flow, and increased evaporation rate range at 35–45% relative humidity (RH) (p<0.05) were also detected. Other related tear parameters did not change. Meibomian gland dropout showed no improvement.

Conclusions: 3 months of oral minocycline resulted in clinical improvements in all meibomianitis signs that persisted for at least 3 months after discontinuation despite decreased aqueous tear volume and flow with increased evaporation (35–45% RH). However, there was improvement in the turbidity of secretions. Short term minocycline therapy probably has efficacy in the management of meibomianitis that extends beyond eradication of bacteria.

Footnotes

  • The authors have no proprietary interest in any product or concept discussed in this paper.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2006.091579v1
    2. 90/7/856 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.